Merck Co#39;s COVID-19 pill cuts risk of death, hospitalization by 50% in study

Merck Co#39;s COVID-19 pill cuts risk of death, hospitalization by 50% in study Merck and partner Ridgeback Biotherapeutics plan to seek U.S. emergency use authorization for the pill as soon as possible, and to submit applications to regulatory agencies worldwide. Due to the positive results, the Phase 3 trial is being stopped early at the recommendation of outside monitors.

No comments:

Post a Comment